US FDA pauses Gilead trials testing experimental HIV pill combination
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Wall St ends mixed as tech megacap declines outweigh upbeat chip outlook
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- IBM surges on unveiling sub-1nm chip technology breakthrough
- 'Long-term deals significant positive for stock:' Analysts react to Micron results
- Two major earthquakes strike Venezuela, killing at least 32 and injuring hundreds
- Needham Starts NeoVolta (NEOV) at Buy
- Hertz cuts guidance, announces notes and stock offerings, shares sink
- Rockstar Games opens GTA VI pre-orders, priced at $79.99
- Rubio meets Gulf leaders, pledges security amid Iran deal doubts
FDA clinical hold a 'blow to Gilead Sciences (GILD) HIV pipeline - Oppenheimer
June 10, 2025 11:14 AM EDTOppenheimer analyst Hartaj Singh reiterated an Outperform rating and $125.00 price target on Gilead Sciences (NASDAQ: GILD) but said the clinical hold is a 'blow' to the company's HIV pipeline.
The analyst commented, "This morning, Gilead announced that the FDA had put ongoing GS-4182+GS-1720... More
